tradmap

STAA Staar Surgical Co

$26.71 -1.51%

Data as of close

Healthcare · Ophthalmic Goods

Staar Surgical Co (STAA) is a healthcare company in the Ophthalmic Goods industry, with a market capitalization of $1.3 billion. Shares last traded at $26.71, 25.2% below their 52-week high. Over the past year the stock is up 5.7%. STAA trades at a price-to-earnings ratio of 2529.98, above the Ophthalmic Goods median of 231.29. Net profit margin is 0.2%, below the peer median of 0.5%. Revenue declined 23.7% year over year.

Market Cap
$1.3B
Shares Out
50.2M
EPS (TTM)
$0.01
P/E (TTM)*
2529.98
P/S Ratio
4.08
P/B Ratio
3.56
Dividend / Share
—
Dividend Yield
—
52-Week High
$35.70
52-Week Low
$15.59
Volume (venue)
123,694
Avg Vol (3m, venue)
50,599.159

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+5.85%
1M
+19.51%
3M
+10.33%
6M
-2.09%
YTD
+15.60%
1Y
+5.70%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
69.27
SMA (50)
$22.65
SMA (200)
$23.74
Price vs SMA50
+17.94%
Price vs SMA200
+12.51%
ATR (14)
$1.19

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$328M
Net Income
$530000
Gross Margin
73.6%
Operating Margin
0.2%
Net Margin
0.2%
Return on Equity
0.1%
Return on Assets
0.1%
Current Ratio
4.68
Debt / Equity
0.29
Revenue Growth (YoY)
-23.7%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-10-02. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 $0.11 2026-11-04
Q2 2026 $0.16 2026-08-12
Q1 2026 $0.10 2026-05-13
Q4 2025 (derived) -$0.36 2026-03-03
FY 2025 -$1.62 2026-03-03
Q3 2025 $0.18 2025-11-05

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Ophthalmic Goods peers

STAA vs 8 industry peers (Ophthalmic Goods), by market cap. Data as of close

P/E vs peers
2529.98 / 231.29 med
+994% premium
P/S vs peers
4.08 / 2.25 med
+82% premium
Net margin vs peers
0.2% / 0.5% med
below median
1–8 of 8
ALCAlcon Inc$37.3B———-1.02%
COOCooper Companies (The)$12.1B21.172.8513.5%-1.44%
BLCOBausch & Lomb Corp$7.1B—1.32-2.0%-3.30%
WRBYWarby Parker Inc.$3.2B434.463.470.8%+22.76%
EYENational Vision Holdings, Inc.$1.4B28.110.702.5%-0.28%
STAAStaar Surgical Co$1.3B2529.984.080.2%-1.51%
RXSTRxsight, Inc.$190M—1.64-46.3%-9.24%
LUCYInnovative Eyewear Inc$7M———+0.79%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.